Lowest Price Guaranteed
Pages
400
Last Updated
July 2026
View Count
9841
1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control
3. MARKET DYNAMICS
3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations
4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion
5. EXECUTIVE SUMMARY
6. INTRODUCTION
6.1. Chapter Overview
6.2. Medication Adherence
6.2.1. Digital Tools for Improving Medication Adherence
6.3. Overview of Medication Adherence
6.4. Key Design Features and Development Process
6.5. Classification of Medication Adherence
6.5.1. Type of Device
6.5.1.1. Smart Inhalers
6.5.1.2. Smart Handheld Injectors
6.5.1.3. Smart Pills
6.5.1.4. Smart Implantable Devices
6.5.2. Type of Technology
6.6. Regulatory Guidelines for Medication Adherence
6.7. Advantages and Limitations of Medication Adherence
6.8. Impact of COVID-19 on Medication Adherence Domain
6.9. Future Perspective
7. MARKET LANDSCAPE: MEDICATION ADHERENCE
7.1. Chapter Overview
7.2. Medication Adherence: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Launch Year
7.2.3. Analysis by Type of Integrated Device
7.2.4. Analysis by Route of Administration
7.2.5. Analysis by Target Indication
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Key Features
7.2.8. Analysis by Mode of Connectivity
7.2.9. Analysis by Availability of Companion Mobile Application
7.2.10. Analysis by Availability of Data Storage / Cloud Platform
7.3. Medication Adherence Manufacturers: Overall Market Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Year of Establishment and Location of Headquarters
7.3.5. Analysis by Company Size and Location of Headquarters
7.3.6. Most Active Players: Analysis by Number of Medication Adherence Manufactured
8. MARKET LANDSCAPE: ADD-ON SENSORS
8.1. Chapter Overview
8.2. Add-on Sensors: Overall Market Landscape
8.2.1. Analysis by Stage of Development
8.2.2. Analysis by Launch Year
8.2.3. Analysis by Compatible Device
8.2.4. Analysis by Route of Administration
8.2.5. Analysis by Target Indication
8.2.6. Analysis by Therapeutic Area
8.2.7. Analysis by Key Features
8.2.8. Analysis by Mode of Connectivity
8.2.9. Analysis by Availability of Companion Mobile Application
8.2.10. Analysis by Availability of Data Storage / Cloud Platform
8.3. Add-on Sensor Manufacturers: Overall Market Landscape
8.3.1. Analysis by Year of Establishment
8.3.2. Analysis by Company Size
8.3.3. Analysis by Location of Headquarters
8.3.4. Analysis by Year of Establishment and Location of Headquarters
8.3.5. Analysis by Company Size and Location of Headquarters
8.3.6. Most Active Players: Analysis by Number of Add-on Sensors Manufactured
9. PRODUCT COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Medication Adherence: Product Competitiveness Analysis
9.4.1. Smart Drug Delivery Devices
9.4.1.1. Smart Handheld Injectors (Peer Group 1a)
9.4.1.2. Smart Wearable Injectors (Peer Group 1b)
9.4.1.3. Other Integrated Devices (Peer Group 1c)
9.4.2. Add-on Sensors (Peer Group 2)
10. COMPANY PROFILES: MEDICATION ADHERENCE DEVICE MANUFACTURERS BASED IN NORTH AMERICA
10.1. Chapter Overview
10.2. Leading Medication Adherence Device Manufacturers
10.2.1. Medtronic
10.2.1.1. Company Overview
10.2.1.2. Financial Information
10.2.1.3. Medication Adherence Portfolio
10.2.1.4. Recent Developments and Future Outlook
10.2.2. Insulet
10.2.3. Tandem Diabetes Care
10.2.4. Bigfoot Biomedical
10.2.5. Phillips-Medisize
10.2.6. West Pharmaceutical Services
11. COMPANY PROFILES: MEDICATION ADHERENCE DEVICE MANUFACTURERS BASED IN EUROPE
11.1. Chapter Overview
11.2. Leading Medication Adherence Device Manufacturers
11.2.1. BIOCORP
11.2.1.1. Company Overview
11.2.1.2. Financial Information
11.2.1.3. Medication Adherence Portfolio
11.2.1.4. Recent Developments and Future Outlook
11.2.2. Gerresheimer
11.2.3. Roche
11.2.4. Ypsomed
11.2.5. Nemera
11.2.6. Sonceboz
12. COMPANY PROFILES: MEDICATION ADHERENCE DEVICE MANUFACTURERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD
12.1. Chapter Overview
12.2. Leading Medication Adherence Device Manufacturers
12.2.1. Medtrum
12.2.1.1. Company Overview
12.2.1.2. Medication Adherence Portfolio
12.2.1.3. Recent Developments and Future Outlook
12.2.2. SOOIL Development
12.2.3. EOFlow
12.2.4. Eitan Medical
12.2.5. E3D Elcam Drug Delivery Device
13. CLINICAL TRIAL ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Medication Adherence: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
13.3.3. Analysis by Trial Status
13.3.4. Analysis by Trial Registration Year and Trial Status
13.3.5. Analysis of Number of Enrolled Patients Population by Trial Status
13.3.6. Analysis by Target Patient Population
13.3.7. Analysis by Type of Sponsor / Collaborator
13.3.8. Analysis by Study Design
13.3.8.1. Analysis by Type of Allocation
13.3.8.2. Analysis by Type of Intervention Model
13.3.8.3. Analysis by Type of Masking
13.3.8.4. Analysis by Trial Purpose
13.3.9. Leading Players: Analysis by Number of Registered Trials
13.3.10. Leading Medication Adherence: Analysis by Number of Registered Trials
13.3.11. Analysis by Geography
13.3.11.1. Analysis of Clinical Trials by Geography
13.3.11.2. Analysis of Number of Registered Trials by Trial Status and Geography
13.3.11.3. Analysis of Number of Enrolled Patient Population by Geography
14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. Medication Adherence: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Year and Type of Partnership
14.3.4. Analysis by Class of Device
14.3.5. Analysis by Type of Integrated Device
14.3.6. Most Active Players: Analysis by Number of Partnerships
14.3.7. Analysis by Geography
14.3.7.1. Intracontinental and Intercontinental Deals
14.3.7.2. Local and International Deals
15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Funding Models
15.3. Medication Adherence: Funding and Investments
15.3.1. Analysis by Year of Funding
15.3.2. Analysis by Type of Funding
15.3.3. Analysis by Year and Type of Funding
15.3.4. Analysis of Amount Invested by Year of Funding
15.3.5. Analysis of Amount Invested by Type of Funding
15.3.6. Analysis by Geography
15.3.7. Most Active Players: Analysis by Number of Funding Instances
15.3.8. Most Active Players: Analysis by Amount Raised
16. VALUE CHAIN / COST PRICE ANALYSIS
16.1. Chapter Overview
16.2. Medication Adherence: Value Chain
16.3. Cost Distribution across the Value Chain
16.3.1. Concept Development and Proof of Concept
16.3.2. Research and Product Development
16.3.3. Conduct of Clinical Trials
16.3.4. Regulatory Approvals
16.3.5. Manufacturing and Product Assembly
16.3.6. Application Development
16.3.7. Marketing and Sales
17. REGULATORY LANDSCAPE FOR MEDICATION ADHERENCE
17.1. Chapter Overview
17.2. Regulatory Approval of Combination Products in North America
17.2.1. Regulatory Approval of Combination Products in the US
17.2.1.1. Overview
17.2.1.2. Historical Background
17.2.1.3. Role of Regulatory Bodies in Product Approval
17.2.2. Regulatory Approval of Combination Products in Canada
17.2.2.1. Overview
17.2.2.2. Role of Regulatory Bodies in Product Approval
17.2.3. Regulatory Approval of Combination Products in Mexico
17.2.3.1. Overview
17.2.3.2. Role of Regulatory Bodies in Product Approval
17.3. Regulatory Approval of Combination Products in Europe
17.3.1. Regulatory Approval of Combination Products in EU5 Countries
17.3.1.1. Overview
17.3.1.2. Role of Regulatory Bodies in Product Approval
17.4. Regulatory Approval of Combination Products in Asia-Pacific
17.4.1. Regulatory Approval of Combination Products in Japan
17.4.1.1. Overview
17.4.1.2. Role of Regulatory Bodies in Product Approval
17.4.2. Regulatory Approval of Combination Products in China
17.4.2.1. Overview
17.4.2.2. Role of Regulatory Bodies in Product Approval
17.4.3. Regulatory Approval of Combination Products in India
17.4.3.1. Overview
17.4.3.2. Role of Regulatory Bodies in Product Approval
17.4.4. Regulatory Approval of Combination Products in South Korea
17.4.4.1. Overview
17.4.4.2. Role of Regulatory Bodies in Product Approval
17.4.5. Regulatory Approval of Combination Products in Australia
17.4.5.1. Overview
17.4.5.2. Role of Regulatory Bodies in Product Approval
17.5. Regulatory Approval of Combination Products in Middle East and North Africa
17.5.1. Regulatory Approval of Combination Products in Saudi Arabia
17.5.1.1. Overview
17.5.1.2. Role of Regulatory Bodies in Product Approval
17.5.2. Regulatory Approval of Combination Products in United Arab Emirates
17.5.2.1. Overview
17.5.2.2. Role of Regulatory Bodies in Product Approval
17.6. Regulatory Approval of Combination Products in Latin America
17.6.1. Regulatory Approval of Combination Products in Brazil
17.6.1.1. Overview
17.6.1.2. Role of Regulatory Bodies in Product Approval
17.6.2. Regulatory Approval of Combination Products in Argentina
17.6.2.1. Overview
17.6.2.2. Role of Regulatory Bodies in Product Approval
17.7. Connected Devices: Other Measures for Testing Safety, Effectiveness and Performance
17.8. Ensuring Security of Data Captured
17.9. Concluding Remarks
18. CASE STUDIES: APPLICATION OF CONNECTED DRUG DELIVERY DEVICES TO IMPROVE MEDICATION ADHERENCE
18.1. Chapter Overview
18.2. Case Study I: Diabetes
18.2.1. Disease Overview
18.2.2. Key Statistics
18.2.3. Economic Burden due to Non-Adherence
18.2.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence
18.3. Case Study II: Asthma
18.3.1. Disease Overview
18.3.2. Key Statistics
18.3.3. Economic Burden due to Non-Adherence
18.3.4. Evolution of Connected / Smart Drug Delivery Devices for Improving Adherence
19. SWOT ANALYSIS
19.1. Chapter Overview
19.2. Strengths
19.3. Weaknesses
19.4. Opportunities
19.5. Threats
19.6. Comparison of SWOT Factors
20. BLUE OCEAN STRATEGY
20.1. Overview of Blue Ocean Strategy
20.1.1. Red Oceans
20.1.2. Blue Oceans
20.1.3. Comparison of Red Ocean Strategy and Blue Ocean Strategy
20.1.4. Connected Drug Delivery Devices: Blue Ocean Strategy and Shift Tools
20.1.4.1. Strategy Canvas
20.1.4.2. Pioneer-Migrator-Settler (PMS) Map
21. GLOBAL MEDICATION ADHERENCE MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global Medication Adherence Market: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2. Optimistic Scenario
21.4. Key Market Segmentations
22. MEDICATION ADHERENCE MARKET, BY TYPE OF SOLUTION
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Medication Adherence Market: Distribution by Type of Solution
22.3.1. Medication Adherence Market for Hardware Centric: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
22.3.2. Medication Adherence Market for Software Centric: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation
23. MEDICATION ADHERENCE MARKET, BY TYPE OF PRODUCT
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Medication Adherence Market: Distribution by Type of Product
23.3.1. Medication Adherence Market for Smart Inhalers: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.2. Medication Adherence Market for Smart Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.3. Medication Adherence Market for Smart Wearable Injectors: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.4. Medication Adherence Market for Smart Pills: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.5. Medication Adherence Market for Smart Medication Dispensers: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.6. Medication Adherence Market for Smart Pills Bottles / Caps and Boxes: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.7. Medication Adherence Market for Smart Blisters Packs: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.3.8. Medication Adherence Market for Others: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation
24. MEDICATION ADHERENCE MARKET, BY ROUTE OF ADMINISTRATION
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Medication Adherence Market: Distribution by Route of Administration
24.3.1. Medication Adherence Market for Oral: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.3.2. Medication Adherence Market for Injectables: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.3.3. Medication Adherence Market for Inhalable: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.3.4. Medication Adherence Market for Others: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
24.4. Data Triangulation and Validation
25. MEDICATION ADHERENCE MARKET, BY THERAPEUTIC AREA
25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Medication Adherence Market: Distribution by Therapeutic Area
25.3.1. Medication Adherence Market for Metabolic Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.3.2. Medication Adherence Market for Cardiovascular Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.3.3. Medication Adherence Market for Neurological and Central Nervous System Related Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.3.4. Medication Adherence Market for Respiratory Disorders: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.3.5. Medication Adherence Market for Others: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation
26. MEDICATION ADHERENCE MARKET, BY END-USER
26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Medication Adherence Market: Distribution by End-user
26.3.1. Medication Adherence Market for Hospitals: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
26.3.2. Medication Adherence Market for Home Care Settings: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
26.3.3. Medication Adherence Market for Others: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation
27. MEDICATION ADHERENCE MARKET, BY GEOGRAPHICAL REGIONS
27.1. Chapter Overview
27.2. Assumptions and Methodology
27.3. Medication Adherence Market: Distribution by Geographical Regions
27.3.1. Medication Adherence Market in North America: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.1.1. Medication Adherence Market in the US: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.1.2. Medication Adherence Market in Canada: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2. Medication Adherence Market in Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.1. Medication Adherence Market in the UK: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.2. Medication Adherence Market in Germany: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.3. Medication Adherence Market in France: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.4. Medication Adherence Market in Italy: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.5. Medication Adherence Market in Spain: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.2.6. Medication Adherence Market in Rest of Europe: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.3. Medication Adherence Market in Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.3.1. Medication Adherence Market in China: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.3.2. Medication Adherence Market in India: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.3.3. Medication Adherence Market in Japan: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.3.3.4. Medication Adherence Market in Rest of Asia-Pacific: Historical Trends (since 2020) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and
28. CONCLUDING REMARKS
29. EXECUTIVE INSIGHTS
29.1. Chapter Overview
29.2. Company A
29.2.1. Company Snapshot
29.2.2. Interview Transcript: Senior Director, Global Strategic Marketing, Medical
29.3. Company B
29.3.1. Company Snapshot
29.3.2. Interview Transcript: Co-founder and Chief Executive Officer
29.4. Company C
29.4.1. Company Snapshot
29.4.2. Interview Transcript: Founder and Chief Executive Officer
29.5. Company D
29.5.1. Company Snapshot
29.5.2. Interview Transcript: Chief Executive Officer and President
29.6. Company E
29.6.1. Company Snapshot
29.6.2. Interview Transcript: Chief Executive Officer
29.7. Company F
29.7.1. Company Snapshot
29.7.2. Interview Transcript: Vice President and Chief Scientist
29.8. Company G
29.8.1. Company Snapshot
29.8.2. Interview Transcript: Director (Global Communications) and Former Vice President (Strategic Partnerships and Business Development)
29.9. Company H
29.9.1. Company Snapshot
29.9.2. Interview Transcript: Former Chief Executive Officer
29.10. Company I
29.10.1. Company Snapshot
29.10.2. Interview Transcript: Former Director (Front-end Innovation and Head of Connected Health)
29.11. Company J
29.11.1. Company Snapshot
29.11.2. Interview Transcript: Former Vice President (Marketing and Alliance Management)
29.12. Company K
29.12.1. Company Snapshot
29.12.2. Interview Transcript: Advisor (Strategy and Business Development)
29.13. Company L
29.13.1. Company Snapshot
29.13.2. Interview Transcript: Associate
29.14. Company M
29.14.1. Company Snapshot
29.14.2. Interview Transcript: Director, Associate Professor
29.15. Company N
29.15.1. Company Snapshot
29.15.2. Interview Transcript: Chief Pharmacy Officer, Policy Analyst
29.16. Company O
29.16.1. Company Snapshot
29.16.2. Interview Transcript: Chief Executive Officer
29.17. Company P
29.17.1. Company Snapshot
29.17.2. Interview Transcript: Chief Executive Officer
29.18. Company Q
29.18.1. Company Snapshot
29.18.2. Interview Transcript: Chief Experience Officer
29.19. Company R
29.19.1. Company Snapshot
29.19.2. Interview Transcript: Chief Medical Officer
29.20. Company S
29.20.1. Company Snapshot
29.20.2. Interview Transcript: Co-Founder and Board Member
29.21. Company T
29.21.1. Company Snapshot
29.21.2. Interview Transcript: Chief Executive Officer
29.22. Company U
29.22.1. Company Snapshot
29.22.2. Interview Transcript: Chief Executive Officer
29.23. Company V
29.23.1. Company Snapshot
29.23.2. Interview Transcript: Chief Executive Officer
29.24. Company W
29.24.1. Company Snapshot
29.24.2. Interview Transcript: Chief Optimus
29.25. Company X
29.25.1. Company Snapshot
29.25.2. Interview Transcript: Chief Technical Officer and Chief Scientific Officer
29.26. Company Y
29.26.1. Company Snapshot
29.26.2. Interview Transcript: Co-Founder and Chief Executive Officer
30. APPENDIX 1: TABULATED DATA
31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS